Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp46 | Bone & Calcium Homeostasis (1) | ECE2016

Denosumab increases bone mineral density in primary hyperparathyroidism treated with cinacalcet

Munoz Jimenez Concepcion , Manuel Quesada Gomez Jose , Moreno Moreno, Maria Rosa Alhambra Exposito Paloma , Inmaculada Prior Sanchez Maria , Angeles Galvez Moreno Maria

Cinacalcet decreases and normalizes serum calcium levels across a broad severity range of primary hyperparathyroidism (PHPT), slightly reduces parathyroid hormone levels which generally remains elevated, whereas it has no effect on bone mineral density (BMD). Therefore, when administering cinacalcet to a patient with PHPT, concomitant treatment with an anti-catabolic drug should be considered.An open-labeled, prospective trial was conducted in 32 patient...